Reverse pseudohyperkalemia: Verify potassium levels before initiating treatment

Yasir Ahmed, Mustafeez Ur Rahman, Jessica Houston, Emad Al Jaber

ABSTRACT

Hyperkalemia is a complex laboratory abnormality. There are varying degrees of true hyperkalemia, pseudohyperkalemia, and even reverse pseudohyperkalemia which must be distinguished from one another. We present a case of reverse pseudohyperkalemia in an elderly male with a hematologic malignancy found to have an elevated potassium level on admission. Both plasma and serum levels were measured, plasma level was high while serum levels were normal, and a diagnosis of reverse pseudohyperkalemia was made. Awareness and increased suspicion result in rapid diagnosis, and prevent overtreatment and iatrogenic complications.

Keywords: Hyperkalemia, Pseudohyperkalemia, Reverse pseudohyperkalemia

INTRODUCTION

Hyperkalemia is defined as K+ levels greater than 5.0 mEq/L and is further classified as mild, moderate, and severe. Hyperkalemia is a potentially life-threatening laboratory abnormality that occurs in a number of conditions including renal failure, rhabdomyolysis, medication side effects, etc., and requires prompt diagnosis and treatment. It is crucial to differentiate true hyperkalemia from pseudohyperkalemia which is defined as an in vitro increase in the concentration of potassium in the serum without any electrolyte disturbances clinically [1–4]. This has been reported in condition resulting in lymphocytosis and/or thrombocytosis. Reverse pseudohyperkalemia is defined as a rise in the concentration of potassium in the plasma when the serum concentration is normal which is opposite to the phenomenon seen in pseudohyperkalemia and can be seen in conditions like chronic lymphocytic leukemia (CLL) [5, 6].

CASE REPORT

A 60-year-old African American male with history of diffuse lymphadenopathy currently undergoing evaluation at Hematology/Oncology clinic for underlying malignancy presented to the emergency department with hyperkalemia and concerns for possible tumor lysis syndrome (TLS). The patient denied any acute complaints and was hemodynamically stable on presentation. Physical exam was unremarkable except for pallid conjunctivae and diffuse lymphadenopathy. Initial labs revealed a hemoglobin 9.8 g/dL (13.5–17.5 g/dL), white blood cells (WBCs) >440×10^3/mm^3 (4000–11,000/mm^3), creatinine (Cr) 0.7 mg/dL (0.6–1.2 mg/dL), no laboratory evidence of TLS, and a serum potassium (K+) level of 7.3 mEq/L (normal 3.5–5.1 mEq/L). Electrocardiogram (EKG) obtained at presentation showed sinus rhythm without
peaked T waves. A venous i-STAT reported K⁺ level of 8.1 mEq/L. Potassium levels were then checked in two different blood samples with serum K⁺ level of 3.5 mEq/L and plasma K⁺ levels of 6.2 mEq/L. An arterial i-STAT later confirmed K⁺ level of 3.5 mEq/L. A Foley catheter was placed and confirmed adequate urine output (UOP). A diagnosis of reverse pseudohyperkalemia was made based on the above findings. K⁺ was measured in serum samples thereafter for accurate measurement.

DISCUSSION

Hyperkalemia may cause nonspecific generalized symptoms, such as fatigue, nausea, vomiting, muscle weakness, and paresthesias. The most life-threatening effect of hyperkalemia is the effect on the myocardium. It must be quickly recognized and treated because of the high risk of lethal arrhythmias and cardiac arrest. On the other hand, identifying the presence of pseudohyperkalemia is crucial to avoid the complications caused by treating pseudohyperkalemia and thereby inducing actual hypokalemia [7, 8].

Markedly incorrect K⁺ levels can occur in pseudohyperkalemia and reverse pseudohyperkalemia (also known as pseudo-pseudo-hyperkalemia). Pseudohyperkalemia is a well-recognized entity occurring when the serum K⁺ levels are falsely elevated, and the plasma K⁺ level is normal. Plasma and serum values are obtained from the liquid portion of the blood, however serum is the liquid after blood has clotted while plasma is the liquid obtained after clotting has been prevented using anticoagulant. The serum K⁺ concentration normally exceeds the true value in the plasma by 0.1 to as much as 0.5 mEq/L due to K⁺ release from white cells and platelets during the clotting process. Experts suggest a difference of 0.4 mEq/L between serum and plasma potassium concentration for consideration of pseudohyperkalemia (provided that both the samples were within an hour of collection and were kept at room temperature) [4, 9]. In such cases, the clinical decisions should be based on the plasma, not the serum K⁺ concentration. Mechanical trauma during venipuncture (hemolysis) is the most common cause of pseudohyperkalemia. K⁺ movement out of the cells (erythrocytes, leukocytes, or platelets) either during or after drawing of the blood specimen results in pseudohyperkalemia. The measured serum K⁺ concentration may be falsely high (up to 9 mEq/L) in patients with marked leukocytosis (white cell count >70,000/mm³) or thrombocytosis (platelet count >500,000/mm³). With thrombocytosis, for example, the measured serum K⁺ concentration rises by approximately 0.15 mEq/L for every 100,000/mm³ elevation in the platelets count. Thrombocytes undergo degranulation and aggregation during the clotting process while also releasing K⁺, thus leading to elevated serum K⁺ concentration [2, 4]. The causes of pseudohyperkalemia are summed up in Table 1 [7]. The presence of pseudohyperkalemia should be strongly suspected whenever hyperkalemia and hemolysis, extreme leukocytosis, or thrombocytosis coexists. It should also be considered in the absence of apparent cause for the elevation in K⁺ levels (impaired renal function, combination of K⁺ raising drugs), in the absence of EKG changes and when there are no changes in muscle strength. It is worth mentioning that hyperkalemia is exceedingly rare if renal function is normal.

Reverse pseudohyperkalemia is a phenomenon opposite to what has been described earlier for pseudohyperkalemia, i.e., plasma K⁺ levels are higher than serum K⁺ levels (differentials based on serum and plasma K⁺ levels are summed in Table 2). It is commonly seen in patients with hematological malignancies, especially CLL [9, 10]. The true underlying mechanism is unclear, however there are certain theories for the pathology behind this phenomenon based on the observations of the clinicians and the lab personnel. Routine serum analysis shows elevated measured potassium levels resulting from release of potassium from the fragile leukemic cells.

Table 1: Factors causing pseudohyperkalemia [7]

| Causes of pseudohyperkalemia | Examples |
|-------------------------------|---------|
| **Causative factors** | |
| Mechanical | Prolonged tourniquet use |
| | Fist clenching |
| | Traumatic venipuncture or probing |
| | Inappropriate needle diameter |
| | Excessive force with syringe draws |
| | Diameter mismatch of the catheter, tube adapter device, and needle |
| | Pneumatic tube transport/unpadded canisters |
| | Specimen processing (vigorous mixing, excessive centrifugal force, prolonged fixed angle centrifugation, or recentrifugation of gel separator tubes |
| Chemical | Incomplete drying of ethanol containing antiseptics before venipuncture |
| Temperatures | Specimens not stored at 15–25°C |
| Time | Delayed processing |
| Patient related | Acute respiratory alkalosis |
| | Thrombocytosis |
| | Erythrocytosis |
| | Leukocytosis/WBC neoplasms |
| | Postsplenectomy state |
| | Familial pseudohyperkalemia |
| Contaminants | Potassium-containing intravenous (IV) fluids |
| Miscellaneous | Tube additives containing potassium salts |
| | Plasma reference ranges |
| | Mislabling |
during the clotting process. But in CLL, even the plasma levels of potassium are elevated. Severe leukocytosis leads to consumption of metabolic fuels that impair Na-K ATPase activity, leading to release of potassium from a large number of white blood cells [11–14]. Spuriously elevated K⁺ concentrations were seen with elevated white blood cell count in a longitudinal study [15]. Another proposed mechanism is the damage to the membrane of the millions of fragile malignant cells by the heparin in the tubes used for the collection of these samples [5, 9, 16]. In several studies, it was found that the K⁺ level in plasma was higher in heparinized tubes than the K⁺ levels obtained simultaneously in non-heparinized tubes and the extent to which the K⁺ concentration was increased was proportionally related to the amount of heparin present in the tubes [6, 8]. Mechanical stressors can also attribute to the damage to these cells.

Experts suggest a difference of 0.4 mEq/L between serum and plasma potassium concentration for consideration of pseudo-hyperkalemia or reverse pseudo-hyperkalemia, provided that both the samples were within an hour of collection and were kept at room temperature [4, 9].

Basically, our patient had normal renal function and good urine output. He had normal serum bicarb with no evidence of RTA and was not taking any potassium sparing diuretics. His white blood cell count was >440×10³/mm³ and he continues remained asymptomatic. It is well-known that one of the most common electrolyte disorders encountered in CLL patients is pseudo-hyperkalemia and so was the case in our patient.

The incidence and severity of the pseudo-hyperkalemia in chronic leukocytic leukemia was studied in over 300 patients with CLL listed in the Minnesota Tumor Registry between 1997 and 2014 [15]. So far, this is the first and only study to systematically look at serum and plasma potassium values in CLL patients, demonstrating that the results are related to pseudo-hyperkalemia. For every 10×10⁹/L increase in white blood cell count, an increase in adjusted odds by 1.4 was observed. The median estimated percentage of patient’s serum potassium elevation was 1.7% for WBC counts of 50×10⁹/L, but when the WBC count was ≥100×10⁹/L, it was considerably higher at 8.1% [15].

The different kinds of tubes for blood specimen collection and the color on the top of the tube is the code for the different chemicals in them (Figure 1):

1. Blue-top tube—Sodium citrate (Na citrate).
2. Lavender-top tube—EDTA.
3. Red-top tube—This tube has no anticoagulant.
4. Navy blue-top tube—There are two general types: one with K₂ EDTA and one with no anti-coagulant.
5. Green-top tube—Sodium heparin or lithium heparin.
6. Serum Separator Tube (SST®)—This tube contains a clot activator and serum gel separator. It has no anti-coagulant.
7. Grey-top tube—Fluoride.

Yellow/gold top can be used for sample collection to measure K⁺ as it does not contain any chemical but delay in transport, nonoptimal temperature, and mechanical stressors can cause inaccurate results. ABG remains the analysis of choice and is an extremely quick and reliable test due to the shorter interval between drawing of the sample and analysis [17].

**CONCLUSION**

Presence of hyperkalemia with normal renal function, normal EKG, absence of clinical signs of hyperkalemia, absence of acid-base abnormalities and, in this case, the presence of extreme leukocytosis should raise suspicion for pseudo-hyperkalemia or reverse pseudo-hyperkalemia.

---

Table 2: Differentials of elevated potassium (K⁺) levels

| Condition                      | Serum K⁺ | Plasma K⁺ |
|-------------------------------|----------|-----------|
| Hyperkalemia                  | High     | High      |
| Pseudohyperkalemia            | Falsely high | Normal    |
| Reverse pseudohyperkalemia    | Normal   | Falsely high |

Figure 1: Tubes (vacutainers) for blood specimen collections.
The exact mechanism of reverse pseudohyperkalemia in extreme leukocytosis is not clear. Initial approach involves getting serum and plasma potassium samples at the same time. A difference between serum and plasma potassium of more than 0.4 mmol/L is suggestive of pseudohyperkalemia or reverse pseudohyperkalemia. Arterial blood gas potassium might be the only accurate way to diagnose pseudohyperkalemia or reverse pseudohyperkalemia in such cases.

REFERENCES

1. Bronson WR, DeVita VT, Carbone PP, Cotlove E. Pseudohyperkalemia due to release of potassium from white blood cells during clotting. N Engl J Med 1966;274(7):369–75.
2. Ifudu O, Markell MS, Friedman EA. Unrecognized pseudohyperkalemia as a cause of elevated potassium in patients with renal disease. Am J Nephrol 1992;12(1–2):102–4.
3. Nijsten MW, de Smet BJ, Dofferhoff AS. Pseudohyperkalemia and platelet counts. N Engl J Med 1991;325(15):1107.
4. Sevastos N, Theodossiades G, Efstathiou S, Papatheodoridis GV, Manesis E, Archimandritis AJ. Pseudohyperkalemia in serum: The phenomenon and its clinical magnitude. J Lab Clin Med 2006;147(3):139–44.
5. Abraham B, Fakhar I, Tikaria A, et al. Reverse pseudohyperkalemia in a leukemic patient. Clin Chem 2008;54(2):449–51.
6. Garwicz D, Karlman M. Early recognition of reverse pseudohyperkalemia in heparin plasma samples during leukemic hyperleukocytosis can prevent iatrogenic hypokalemia. Clin Biochem 2012;45(18):1700–2.
7. Avelar T. Reverse pseudohyperkalemia in a patient with chronic lymphocytic leukemia. Perm J 2014;18(4):e150–2.
8. Asirvatham RJ, Moses V, Bjornson L. Errors in potassium measurement: A laboratory perspective for the clinician. N Am J Med Sci 2013;5(4):255–9.
9. Singh PJ, Zawada ET, Santella RN. A case of ‘reverse’ pseudohyperkalemia. Miner Electrolyte Metab 1997;23(1):58–61.
10. Kellerman PS, Thornbery JM. Pseudohyperkalemia due to pneumatic tube transport in a leukemic patient. Am J Kidney Dis 2005;46(4):746–8.
11. Mansoor S, Holtzman NG, Emadi A. Reverse pseudohyperkalemia: An important clinical entity in chronic lymphocytic leukemia. Case Rep Hematol 2015;2015:930379.
12. Lee HK, Brough TJ, Curtis MB, Polito FA, Yeo KTJ. Pseudohyperkalemia—is serum or whole blood a better specimen type than plasma? Clin Chim Acta 2008;396(1–2):95–6.
13. Ruddy KJ, Wu D, Brown JR. Pseudohyperkalemia in chronic lymphocytic leukemia. J Clin Oncol 2008;26(16):2781–2.
14. Colussi G, Cipriani D. Pseudohyperkalemia in extreme leukocytosis. Am J Nephrol 1995;15(5):450–2.
15. Katkish L, Rector T, Ishani A, Gupta P. Incidence and severity of pseudohyperkalemia in chronic lymphocytic leukemia: A longitudinal analysis. Leuk Lymphoma 2016;57(8):1952–5.
16. Meng QH, Krahn J. Reverse pseudohyperkalemia in heparin plasma samples from a patient with chronic lymphocytic leukemia. Clin Biochem 2011;44(8–9):728–30.
17. Rifkin SI. Pseudohyperkalemia in patients with chronic lymphocytic leukemia. Int J Nephrol 2011;2011:759749.

Author Contributions

Yasir Ahmed – Conception of the work, Design of the work, Acquisition of data, Analysis of data, Interpretation of data, Drafting the work, Revising the work critically for important intellectual content, Final approval of the version to be published, Agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved

Mustafeez Ur Rahman – Acquisition of data, Analysis of data, Interpretation of data, Drafting the work, Revising the work critically for important intellectual content, Final approval of the version to be published, Agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved

Jessica Houston – Acquisition of data, Analysis of data, Interpretation of data, Drafting the work, Revising the work critically for important intellectual content, Final approval of the version to be published, Agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved

Emad Al Jaber – Conception of the work, Design of the work, Analysis of data, Interpretation of data, Drafting the work, Revising the work critically for important intellectual content, Final approval of the version to be published, Agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved

Guarantor of Submission

The corresponding author is the guarantor of submission.

Source of Support

None.

Consent Statement

Written informed consent was obtained from the patient for publication of this article.

Conflict of Interest

Authors declare no conflict of interest.
Data Availability
All relevant data are within the paper and its Supporting Information files.

Copyright
© 2020 Yasir Ahmed et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.
